• Potential break through technology poised

  2021-06-25

  

  Potential break-through technology poised to overcome these above-mentioned limitations is that of the “substrate mediated enzyme prodrug therapy”, SMEPT (Fig. 1). Learning from the previously established enzyme prodrug therapies (EPT) and specifically the antibody-directed EPT (ADEPT) [12], develo

• Plasminogen is composed of five N

  2021-06-25

  

  Plasminogen is composed of five N-terminal kringle domains and a C-terminal serine protease domain. The kringle domains have an affinity to lysine and binding of plasminogen with its receptors is dependent on its lysine interacting kringle domains [10], [28]. In the current report, we show that enol

• Three kinase inhibitors dasatinib type I imatinib

  2021-06-25

  

  Three kinase inhibitors dasatinib (type I), imatinib (type II) and nilotinib (type II), identified initially as inhibitors of tyrosine kinase BCR-ABL, were found to target DDRs in a chemical proteomic profiling study (Bantscheff et al., 2007, Hantschel et al., 2008). These tyrosine kinase inhibitors

• M 1145 br Oxysterols as Key Players in

  2021-06-25

  

  Oxysterols as Key Players in Metabolic Syndrome? Obesity and sedentary lifestyle are on the rise and pose serious threats to people's health and wellbeing. Obesity is often associated with other pathologies and is one of the criteria included in the definition of metabolic syndrome (MetS) (see Gl

• br Enzymes repairing alkylated DNA br Induction of the

  2021-06-25

  

  Enzymes repairing alkylated DNA Induction of the Ada regulon Methylated Ada is a strong activator for ada and alkA promoters. Although much weaker than the methylated form, unmethylated Ada acts alone as an activator for ada and alkA promoters. In contrast, the unmethylated protein present in

• Resistance to SP is linked to point mutations that accumulat

  2021-06-25

  

  Resistance to SP is linked to point mutations that accumulate at several sites in the dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) KNK437 receptor of P. falciparum (Roper et al., 2003). These mutations have been identified in codons 16, 51, 59, 108, and 164 in the dhfr gene an

• Alvocidib flavopiridol is a piperidine chromenone http

  2021-06-24

  

  Alvocidib (flavopiridol) is a piperidine-chromenone derivative (Fig. 6D) that is not FDA approved, but is in clinical trials for breast, endometrial, and several other cancers and hematological malignancies (Table 4) [[100], [101], [102], [103], [104]]. This drug targets CDK9 (IC50 = 3.2 nM) and CDK

• From the general synthetic route we

  2021-06-24

  

  From the general synthetic route, we first synthesized a directed set of analogues of general formula , keeping the synthesis simple by using a symmetrical pyrazole (R=R=Me). The SAR of a set of 30 compounds in the GTPγS binding assay turned out to be quite tight: only 4 (13%) compounds showed moder

• The radial distribution function is given

  2021-06-24

  

  The radial distribution function, , is given by: For pure components and pseudo-components, the constants a and b are calculated as:whereand Tc, Pc and ω are the critical temperature, critical pressure and acentric factor, respectively. Parameters a and b for mixtures are calculated from those of

• While we are taking full responsibility

  2021-06-24

  

  While we are taking full responsibility for any remaining errors and shortcomings of the paper, we would like to thank Dr. Jong-Hyeon Jeong, Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, for offering us insight and literature pointers useful in our quest to

• The third challenge is to

  2021-06-24

  

  The third challenge is to understand the mechanisms of drug resistance. There are several different mechanisms of ES tumor to develop drug resistance. First, cancer stem cells are capable of proliferate and generate tumor cells with new sets of mutations which may harbor different protein targets [1

• br Conflicts of interest br Author contributions

  2021-06-24

  

  Conflicts of interest Author contributions Acknowledgements This work was supported by the University of Brescia (ex 60%) and Siderurgica Leonessa research funds to AF. RR was supported by Associazione Italiana per la Ricerca sul Cancro - AIRC (MFAG 18459 grant). We are grateful to Umberto

• br Disclosure statement br Acknowledgements This

  2021-06-24

  

  Disclosure statement Acknowledgements This research was supported by grants from the National Institutes of Health, NS046400 and AG022971 (SD), and a fellowship from the Korea Research Foundation, KRF-2007-357-E00016 (YTK). The authors thank Dr. Barbara Crain for assistance with the immunologi

• BIBR-1048 Recently Zhao et al have

  2021-06-24

  

  Recently, Zhao et al. have been carried out a study to investigate the relationship between eNOS-4b/a polymorphism and the risk of LCPD in a Chinese population. Their results demonstrated that eNOS polymorphisms may be involved in the etiology of LCPD. However, the number of studies conducted to exa

• Wortmannin receptor br Materials and methods br

  2021-06-24

  

  Materials and methods Results and discussion Conclusions Codon-optimized MGSK-Lys-C was expressed at a high level in an optimized expression system as inclusion bodies. The Lys-C activity reached its maximum with about 9340 nkat/Lculture under standard (chemical) refolding conditions. The r

16728 records 663/1116 page Previous Next First page 上5页 661662663664665 下5页 Last page